Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)

Late-breaking presentation at ACG 2023 showed histologic and endoscopic improvements were maintained with no new safety signals to week 52 with higher dose Dupixent in these children Data reinforce...

Related Keywords

New York ,United States ,Paris ,France General ,France ,Japan ,Tarrytown ,Nathalie Pham ,Vesna Tosic ,Tarik Elgoutni ,Sally Bain ,Arnaud Delepine ,Georged Yancopoulos ,Eva Schaefer Jansen ,Mirna Chehade ,Evan Berland ,Felix Lauscher ,Corentine Driancourt ,Regeneron Velocimmune ,Sharon Chen ,Regeneron Genetics Center ,Euronext ,Exchange Commission ,American College Of Gastroenterology ,Linkedin ,Drug Administration ,Icahn School Of Medicine ,Mount Sinai Center ,Dupilumab Development Program ,Globenewswire Inc ,Regeneron Velocimmune Technology ,Regeneron Pharmaceuticals Inc ,Nasdaq ,Priority Review ,Sinai Center ,Eosinophilic Disorders ,Icahn School ,Biologics License Application ,Dupixent Pediatric Eosinophilic Esophagitis Trial ,Chief Scientific Officer ,Nasal Polyposis ,Prescribing Information ,Forward Looking Statements ,Regeneron Pharmaceuticals ,Product Candidates ,Private Securities Litigation Reform Act ,Statement Regarding Forward Looking ,Markets ,